Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia

Steven T. Bird(Brigham and Women's Hospital), David J. Graham(United States Food and Drug Administration), Bo Kim(National Institutes of Health), Kate Gelperin(United States Food and Drug Administration), Michael Wernecke(Acumen (United States)), Stephen McKean(Acumen (United States)), Thomas MaCurdy(Stanford University), Donna Przepiorka(The University of Texas MD Anderson Cancer Center), Natasha Flowers(Acumen (United States)), Zebulin Kessler(Acumen (United States)), Taehyun Jung(United States Food and Drug Administration), Fang Tian(United States Food and Drug Administration), Rongrong Wang(Acumen (United States)), Jeffrey A. Kelman(Centers for Medicare and Medicaid Services), Corinne Woods(United States Food and Drug Administration), Barry W. Miller, Clara Kim(United States Food and Drug Administration)
JAMA Oncology
December 19, 2019
10.1001/jamaoncol.2019.3994
Cited by 64

Related Papers

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
|Blood|2001|570
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments]
|Blood|1995|539